Medincell partner teva to host investor call on completed phase 3 olanzapine lai data following psych congress 2025 presentation

Montpellier, france--(business wire)--regulatory news: medincell (paris:medcl): data from the completed phase 3 solaris trial to be presented at the 2025 psych congress annual meeting, taking place from september 17 – 21, 2025, in san diego, california teva will host a conference call for analysts and investors on monday, september 22, 2025, at 11:00 am et to discuss these data to access a live webcast of the presentation, visit teva's investor relations website at https://ir.tevapharm.com/even.
TEVA Ratings Summary
TEVA Quant Ranking